Study Utilizing Rilonacept in Gout Exacerbations
Study Utilizing Rilonacept in Gout Exacerbations
This purpose of this clinical research was to determine the efficacy and safety of an
 experimental drug called Rilonacept in participants with an acute gout attack. Participants
 participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin
 alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.
Inclusion Criteria:

 1. Male or female 18 - 70 years of age

 2. Previously met the preliminary criteria of ARA for the classification of the acute
 arthritis of primary gout

 3. Presenting with an acute attack (flare) of gout within 48 hours of pain onset and pain
 of at least moderate severity

 4. Must have at least 1 on the 0-3 scale for the swelling and the tenderness assessments
 of the gouty index joint

 5. Current presentation of acute gout flare in 3 joints or less

 Exclusion Criteria:

 1. Treatment with any non-steroidal anti-inflammatory drug (NSAIDs) or opiates within 48
 hours prior to baseline assessments. Treatment with long-acting NSAIDs within 1 month
 prior to baseline visit. Treatment with naproxen, meloxicam, nabumetone, celecoxib and
 indomethacin SR within 5 days prior to baseline visit.

 2. Treatment with oral analgesics within 6 hours before baseline assessments. Treatment
 with topical analgesics within 12 hours before baseline assessments

 3. History of NSAID intolerance

 4. Participants with history of chronic, gouty arthritis